Late Stage Chronic Kidney Disease Drugs Global Market Report 2024

The late stage chronic kidney disease drugs market size has grown rapidly in recent years. It will grow from $6.38 billion in 2023 to $7.16 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The growth observed in the historic period can be attributed to several factors, including advancements in diagnostic capabilities, an aging population, an increased prevalence of diabetes and hypertension, a heightened awareness of kidney diseases, and the expansion of pharmaceutical research and development.

The late stage chronic kidney disease drugs market size is expected to see rapid growth in the next few years. It will grow to $10.94 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing healthcare expenditure, the adoption of precision medicine approaches, a growing focus on regenerative medicine, a heightened emphasis on patient-centered care, and global initiatives aimed at raising awareness about kidney diseases. Major trends expected in the forecast period encompass the expansion of regenerative medicine therapies, the rise in telemedicine services for chronic kidney disease (CKD) management, the development of combination therapies, a focus on early intervention strategies, and a growing interest in biomarker-based diagnostics.

The anticipated growth in the late-stage chronic kidney disease drug market is expected to be propelled by the high prevalence of chronic kidney diseases. Chronic kidney diseases encompass a diverse range of conditions impacting the structure and function of the kidneys. Late-stage chronic kidney disease drugs are crucial in controlling blood pressure, reducing protein loss, and managing symptoms to halt the progression of kidney impairment and prevent complications. As of July 2022, the Centers for Disease Control and Prevention reported that approximately 15%, or 37 million people in the US, were affected by kidney disease. The prevalence varied across age groups, with individuals aged 45–64 experiencing a 12% prevalence, while those between 18 and 44 had the lowest majority at 6% in 2021. Consequently, the rising prevalence of chronic kidney disease serves as a key driver for the growth of the late-stage chronic kidney disease drug market.

The high prevalence of diabetes is another significant factor expected to drive the growth of the late-stage chronic kidney disease drug market. Diabetes, characterized by elevated blood glucose levels, poses a risk for serious damage to various organs, including the kidneys. Diabetes is a well-established risk factor for the development of chronic kidney disease, especially in its later stages. With the global increase in the prevalence of diabetes, the incidence of late-stage chronic kidney disease is also expected to rise proportionally. For example, as of April 2023, Diabetes UK reported that more than 4.3 million people in the UK are living with diabetes, and an additional 850,000 individuals may have diabetes but remain undiagnosed. Compared to the previous year, these registration numbers increased by 148,591. Notably, almost 2.4 million people in the UK have an elevated risk of developing type 2 diabetes based on blood sugar readings. Consequently, the high prevalence of diabetes is a significant factor driving the growth of the late-stage chronic kidney disease drug market.

Product innovation emerges as a prominent trend gaining traction in the late-stage chronic kidney disease drug market, with major companies actively developing new drugs to maintain their market positions. For example, in February 2022, Bayer, a leading Germany-based pharmaceutical and biotechnology company, introduced Kerendia (finerenone) in India. Finerenone, a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist, is recommended for patients with type two diabetes and chronic renal disease. The drug works by preventing the overactivation of the mineralocorticoid receptor (MR), believed to be a factor in the development of chronic kidney disease (CKD) and cardiovascular harm.

Strategic collaborations are another key focus for major companies operating in the late-stage chronic kidney disease drug market, aiming to create synergies for advancing precision medicines in this field. In March 2021, Evotec SE, a Germany-based drug discovery and development company, collaborated with Chinook Therapeutics, a Canada-based clinical-stage biopharmaceutical company. This strategic partnership is dedicated to discovering and developing novel precision medicines for chronic kidney diseases. By leveraging Evotec's extensive molecular datasets from hundreds of patients with diverse underlying etiologies of chronic kidney diseases, the collaboration aims to identify, characterize, and validate novel mechanisms, ultimately leading to the discovery and development of precision therapies.

In January 2023, AstraZeneca, a UK-based biopharmaceutical and biotechnology company, acquired CinCor Pharma Inc. for $1.3 billion. This strategic acquisition strengthens AstraZeneca's cardiorenal pipeline by adding CinCor's potential medication, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) designed to treat chronic kidney disorders. CinCor Pharma Inc., a US-based clinical-stage biopharmaceutical company, is the developer of baxdrostat. The acquisition enhances AstraZeneca's position in the late-stage chronic kidney disease drug market.

Major companies operating in the late stage chronic kidney disease drugs market report are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc., Shield Therapeutics PLC, Shire plc.

North America was the largest region in the late stage chronic kidney disease drugs market in 2023. The regions covered in the late stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the late stage chronic kidney disease drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary product types of late-stage chronic kidney disease drugs include calcimimetics, vitamin D, sterols, potassium binders, and calcium-based phosphate binders. Calcimimetics, for instance, constitute a class of medications that enhance signaling and reduce parathyroid hormone (PTH) levels by activating the calcium-sensing receptor allosterically. These drugs address various indications related to late-stage chronic kidney disease, such as hyperparathyroidism, hyperphosphatemia, and hyperkalemia. The distribution channels for these drugs typically include hospital pharmacies, online pharmacies, and retail pharmacies.

The late stage chronic kidney disease drugs market research report is one of a series of new reports that provides late stage chronic kidney disease drugs market statistics, including late stage chronic kidney disease drugs industry global market size, regional shares, competitors with a late stage chronic kidney disease drugs market share, detailed late stage chronic kidney disease drugs market segments, market trends and opportunities, and any further data you may need to thrive in the late stage chronic kidney disease drugs industry. This late stage chronic kidney disease drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The late-stage chronic kidney disease drugs market consists of sales of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), and erythropoietin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.